BridgeMD
Serotonin role on brain circuits involved in food avoidance in anorexia nervosa : Study of Gaze control and multimodal Brain imaging.
EU CTIS ID: 2024-519848-33-00
What this study is testing
To evaluate differences in serotonergic transmission measured by PET at the levels of the cerebral networks underlying the control of food intake (including the striatum) between anorexic and control subjects.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 16-35 year old women
- Subgroup 2: STAI Y2 anxiety score < 51
- BMI between 18.5 and 25 kg/ m²
- Absence of a psychological profile of eating disorder or other psychiatric disorders.
- A low level of trait anxiety (< 51 on the STAI-YB) matched the group of patients with the same level.
- Signature of written consent
You likely can't join if
- Subjects with an oral contraception
- Breastfeeding woman
- Subject with heart failure
- Subject treated during the last three months with neuroleptics, and antiparkinsonian drugs, MAO-A or MOA-B inhibitors, tricyclic antidepressants, 5HT reuptake inhibitors, thymoregulators (lithium), antiepileptic dugs, codeine derivatives, morphinics, tramadol-containing products (Topalgic, lxprim…),dopaminergic drugs.
- Subjects with suspected pregnancy; Test β HCG positive prior to examination.
- Subjects for whom MRI is contraindicated (pacemaker, intracerebral clips, prosthesis made of ferromagnetic material or claustrophobia).
See the full eligibility criteria
- 16-35 year old women
- Subgroup 2: STAI Y2 anxiety score < 51
- BMI between 18.5 and 25 kg/ m²
- Absence of a psychological profile of eating disorder or other psychiatric disorders.
- A low level of trait anxiety (< 51 on the STAI-YB) matched the group of patients with the same level.
- Signature of written consent
- Subject affiliated or entitled to a social security scheme
- Fear of weight gain
- Dismorphophobia
- BMI < 17.5 kg/ m²
- Amenorrhea
- Absence of food compulsions and purges
- Subgroup 1: STAI Y2 anxiety score > 51
- Subjects with an oral contraception
- Breastfeeding woman
- Subject with heart failure
- Subject treated during the last three months with neuroleptics, and antiparkinsonian drugs, MAO-A or MOA-B inhibitors, tricyclic antidepressants, 5HT reuptake inhibitors, thymoregulators (lithium), antiepileptic dugs, codeine derivatives, morphinics, tramadol-containing products (Topalgic, lxprim…),dopaminergic drugs.
- Subjects with suspected pregnancy; Test β HCG positive prior to examination.
- Subjects for whom MRI is contraindicated (pacemaker, intracerebral clips, prosthesis made of ferromagnetic material or claustrophobia).
- Subjects unable to sign written consent for participation in the study
- Subject deprived of liberty by a judicial or administrative decision
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.